Business Context and Reporting Period
Mink Therapeutics, Inc. (INKT) filed a Form 8-K on June 17, 2026, reporting the results of its Annual Meeting of Stockholders held on the same date. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The filing details the successful election of three Class II Directors and the ratification of the independent auditor. There are no material changes to financial operations or business strategy disclosed in this specific report.
Corporate Governance and Voting Results
A quorum was established with 3,277,906 shares (65.79% of eligible shares) present or represented by proxy. The stockholders approved the following proposals:
- Proposal 1 (Director Election): Garo Armen, Barbara Ryan, and John Holcomb were elected as Class II Directors for three-year terms expiring in 2029.
- Proposal 2 (Auditor Ratification): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Breakdown for Directors:
| Nominee | For | Against | Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Garo Armen | 2,363,360 | 0 | 32,898 | 881,648 |
| Barbara Ryan | 2,362,760 | 0 | 33,498 | 881,648 |
| John Holcomb | 2,381,491 | 0 | 14,767 | 881,648 |
Voting Breakdown for Auditor Ratification:
- For: 3,249,124
- Against: 26,560
- Abstain: 2,222
- Broker Non-Votes: 0
Investor Verification Checklist
- Verify the terms of the newly elected directors (Garo Armen, Barbara Ryan, John Holcomb) expire at the 2029 Annual Meeting.
- Confirm KPMG LLP's engagement as the independent auditor for the fiscal year ending December 31, 2026.
- Review the Definitive Proxy Statement filed on April 23, 2026, for detailed biographies of the directors and further context on the proposals.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.